Trials / Completed
CompletedNCT05853900
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine
A Randomized Double-blind, Parallel-Group, Virtual Study to Evaluate the Effectiveness and Safety of Two Digital Therapeutics in Late Adolescents and Adults for the Prevention of Episodic Migraine
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 568 (actual)
- Sponsor
- Click Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Randomized study of two digital therapeutics for the prevention of episodic migraine
Detailed description
The purpose of this randomized ReMMi-D trial is to evaluate the effectiveness and safety of two prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adolescents and adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | ReMMi-D Digital Therapeutic | Evaluate the effectiveness and safety of prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adults and adolescents. |
Timeline
- Start date
- 2023-03-28
- Primary completion
- 2024-05-07
- Completion
- 2024-05-07
- First posted
- 2023-05-11
- Last updated
- 2025-07-03
- Results posted
- 2025-07-03
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05853900. Inclusion in this directory is not an endorsement.